VD/VDR- vd-vdr

  • Role: administrator
  • Number of posts: 9356
  • Registration Date: September 2, 2015
  • Website:

Posts by VD/VDR- vd-vdr

Ciproxifan, Antagonists of H3-type histamine receptors exhibit cognitive-enhancing properties in various memory paradigms as well as evidence of antipsychotic activity in normal animals.Ciproxifan is an extremely potent histamine H3 inverse agonist/antagonist.Ciproxifan produces wakefulness and attentiveness in animal studies, and produced cognitive enhancing effects without prominent stimulant effects at relatively low levels of receptor occupancy, and pronounced wakefulness at higher doses.It has therefore been proposed as a potential treatment for sleep disorders such as narcolepsy and to improve vigilance in old age, particularly in the treatment of conditions such as Alzheimer¡¯s disease.It also potentiated the effects of antipsychotic drugs, and has been suggested as an adjuvant treatment for schizophrenia.

 June 21, 2017

prudect name : Ciproxifan, Antagonists of H3-type histamine receptors exhibit cognitive-enhancing properties in various memory paradigms as well as evidence of antipsychotic activity in normal animals.Ciproxifan is an extremely potent…

📌
0💬 read more

Faropenem sodium antibiotics for the carbopenems

prudect name : Faropenem sodium antibiotics for the carbopenemsFaropenem sodium hemipentahydrate Synonyms: CAS NO: 106560-14-9Molecular Formula: 2(C12H14NNaO5S).5(H20)Molecular Weight: 704.67Purity: ≥99%Solubility: Storage: −20°C 2 years CHIR99021 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18514969

📌
0💬 read more

APO866 at low concentrations ranging from 0.09-27 nM induces dose-dependent cytotoxicity in 41 hematologic malignant cells including acute myeloid leukemia [AML], acute lymphoblastic leukemia [ALL], mantle cell lymphoma [MCL], chronic lymphocytic leukemia [CLL], and T-cell lymphoma. APO866 at low concentrations ranging from 0-10 nM induces cell death, this effect is independent of caspase activation but is associated with depolarization of mitochondrial membrane. APO866 at concentrations ranging from 0-10 nM dose-dependently induces depletion of intracellular NAD and ATP contents and cell death in various hematologic cancer cells.APO866 at concentration of 10 nM inhibits PBEF-induced secretion of MMP-3, CCL2, and CXCL8 in HFFF2 cells.

prudect name : APO866 at low concentrations ranging from 0.09-27 nM induces dose-dependent cytotoxicity in 41 hematologic malignant cells including acute myeloid leukemia [AML], acute lymphoblastic leukemia [ALL], mantle cell…

📌
0💬 read more

Fotemustine the nitrosourea class of anti-mitotic cells inhibitor, with and carbamyl alkylation of the role of animal experiments demonstrated its broad-spectrum anti-tumor activity.

prudect name : Fotemustine the nitrosourea class of anti-mitotic cells inhibitor, with and carbamyl alkylation of the role of animal experiments demonstrated its broad-spectrum anti-tumor activity.Fotemustine Synonyms: CAS NO: 92118-27-9Molecular…

📌
0💬 read more

R-Tiacumicin B; Tiacumicin B; OPT-80; PAR-101; 3-(((6-Deoxy-4-O-(3,5-dichloro-2-ethyl-4,6-dihydroxybenzoyl)-2-O-methyl-b-D-mannopyranosyl)oxy)-methyl)-12(R)-[(6-deoxy-5-C-methyl-4-O-(2-methyl-1-oxopropyl)-b-D-lyxo-hexopyranosyl)oxy]-11(S)-ethyl-8(S)-hydroxy-18(S)-(1(R)-hydroxyethyl)-9,13,15-trimethyloxacyclooctadeca-3,5,9,13,15-pentaene-2-one; Lipiarmycin

prudect name : R-Tiacumicin B; Tiacumicin B; OPT-80; PAR-101; 3-(((6-Deoxy-4-O-(3,5-dichloro-2-ethyl-4,6-dihydroxybenzoyl)-2-O-methyl-b-D-mannopyranosyl)oxy)-methyl)-12(R)-[(6-deoxy-5-C-methyl-4-O-(2-methyl-1-oxopropyl)-b-D-lyxo-hexopyranosyl)oxy]-11(S)-ethyl-8(S)-hydroxy-18(S)-(1(R)-hydroxyethyl)-9,13,15-trimethyloxacyclooctadeca-3,5,9,13,15-pentaene-2-one; LipiarmycinFidaxomicin Synonyms: CAS NO: 873857-62-6Molecular Formula: 52H74Cl2O18Molecular Weight: 1058.04Purity: 98% minSolubility: In DMSOStorage: -20°C TL32711 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18514883

📌
0💬 read more

prudect name : FluoxydineSynonyms: 5-Fluoro-3H-pyrimidin-4-oneCAS NO: 671-35-2Molecular Formula: C4H3FN2OMolecular Weight: 114.08Purity: 99%Solubility: Storage: −20°C

prudect name : Fluoxydine Synonyms: 5-Fluoro-3H-pyrimidin-4-oneCAS NO: 671-35-2Molecular Formula: C4H3FN2OMolecular Weight: 114.08Purity: 99%Solubility: Storage: −20°C 2 years R115777 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18514783

📌
0💬 read more

Foretinib(GSK1363089, XL880) is a novel MET and VEGFR2/KDR kinases inhibitor with an IC50 of 0.4 and 0.8 nM for MET and KDR, respectively. Foretinib(GSK1363089, XL880) inhibits HGF receptor family tyrosine kinases with an IC50 of 3 nM for Ron. Foretinib(GSK1363089, XL880) also inhibits KDR, Flt-1, and Flt-4 with IC50 of 0.9, 6.8 and 2.8 nM, respectively. In addition, EXEL-2880 inhibits members of the platelet-derived growth factor receptor family and the angiopoietin-1 receptor Tie-2. Foretinib(GSK1363089, XL880) exhibits modest activity against fibroblast growth factor receptor 1 and epidermal growth factor receptor and is inactive against 50 serine/threonine kinases, including cyclin-dependent kinases and protein kinase C isoforms. To delineate the cellular effect of Foretinib(GSK1363089, XL880), VEGF- induced extracellular signal-regulated kinase phosphorylation was used to assess the effect of the compound on phosphorylation of KDR in human umbilical vein endothelial cells that resulted in an IC50 of 16 nM. Foretinib(GSK1363089, XL880) is the 1st orally available small molecule inhibitor of Met to enter the clinic and appears to be generally well tolerated. Anti-tumor activity has been observed and Foretinib may represent an active treatment option for patients with papillary renal-cell carcinoma.

prudect name : Foretinib(GSK1363089, XL880) is a novel MET and VEGFR2/KDR kinases inhibitor with an IC50 of 0.4 and 0.8 nM for MET and KDR, respectively. Foretinib(GSK1363089, XL880) inhibits HGF…

📌
0💬 read more

Fludarabine (Fludara, F-ara-A, NSC 118218) is a STAT-1 activation inhibitor and a DNA synthesis inhibitor for RPMI 8226 cells with an IC50 of 1.54 ¦Ìg/mL.

prudect name : Fludarabine (Fludara, F-ara-A, NSC 118218) is a STAT-1 activation inhibitor and a DNA synthesis inhibitor for RPMI 8226 cells with an IC50 of 1.54 ¦Ìg/mL.Fludarabine Synonyms: CAS…

📌
0💬 read more

prudect name : FUB 359 maleate saltSynonyms: CAS NO: 184025-19-2Molecular Formula: C16H18N2O2.C4H4O4Molecular Weight: 386.402Purity: 98%

prudect name : FUB 359 maleate salt Synonyms: CAS NO: 184025-19-2Molecular Formula: C16H18N2O2.C4H4O4Molecular Weight: 386.402Purity: 98% minSolubility: In DMSOStorage: -20°C R-roscovitine References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18514730

📌
0💬 read more

R788(FosD) is a selective Syk inhibitor with an IC50 of 41 nM. R788(FosD) has shown clinical activity in heavily pre-treated NHL and CLL patients, exhibits inhibitory activity against SYK but also inhibits a broad spectrum of other kinase targets. In addition to blocking Fc¦ÃR-mediated events, R788 also blocked BCR-mediated Ag presentation, thus broadly interrupting the humoral contributions to T cell-driven autoimmunity. Indeed, oral administration of R788(FosD) significantly delayed spontaneous diabetes onset in NOD mice and successfully delayed progression of early-established diabetes even when treatment was initiated after the development of glucose intolerance. At the DC level, R788 treatment was associated with reduced insulin-specific CD8 priming and decreased DC numbers. At the B cell level, R788(FosD) reduced total B cell numbers and total Ig concentrations. Interestingly, R788(FosD) increased the number of IL-10¨Cproducing B cells, thus inducing a tolerogenic B cell population with immunomodulatory activity. Taken together, Syk in APCs is an attractive target in T cell-mediated autoimmune diseases such as type 1 diabetes.

prudect name : R788(FosD) is a selective Syk inhibitor with an IC50 of 41 nM. R788(FosD) has shown clinical activity in heavily pre-treated NHL and CLL patients, exhibits inhibitory activity…

📌
0💬 read more
« Previous
1 … 807 808 809 810 811 … 936
Next »